Revaccination with locally-produced Vi typhoid polysaccharide vaccine among Chinese school-aged children: Safety and immunogenicity findings

Pediatric Infectious Disease Journal

Volumn 26, Issue 11, 2007, Pages 1001-1005

  Zhou, Wei Zhong ^a   Koo, Hye Won ^b   Wang, Xuan Yi ^b,c   Zhang, Jun ^c   Park, Jin Kyung ^b   Zhu, Fengcai ^a   Deen, Jacqueline ^b   Acosta, Camilo J ^b   Chen, Yan ^d   Wang, Hua ^a   Galindo, Claudia M ^b   Ochiai, Leon ^b   Park, Taesung ^b,e   Von Seidlein, Lorenz ^b   Xu, Zhi Yi ^b   Clemens, John D ^b  

^a JIANGSU PROVINCIAL CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b International Vaccine Institute   (South Korea)

^c FUDAN UNIVERSITY   (China)

^d SHENZHEN CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^e Seoul National University   (South Korea)

Author keywords

Immunogenicity; Revaccination; Safety; Vaccine; Vi polysaccharide

Indexed keywords

BACTERIAL POLYSACCHARIDE; BACTERIUM ANTIBODY; PLACEBO; POLYSACCHARIDE VACCINE; SALMONELLOSIS VACCINE; UNCLASSIFIED DRUG; VI VACCINE;

ABDOMINAL PAIN; ADOLESCENT; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; BRONCHITIS; CHINESE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSPNEA; FEMALE; FOLLOW UP; HUMAN; IMMUNOGENICITY; INJECTION SITE EROSION; INJECTION SITE PAIN; INJECTION SITE RASH; INJECTION SITE SWELLING; MALE; NAUSEA AND VOMITING; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; REVACCINATION; SCHOOL CHILD; TREATMENT OUTCOME; TYPHOID FEVER; UPPER RESPIRATORY TRACT INFECTION; VACCINATION REACTION;

EID: 37349122091     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/INF.0b013e31812565bc     Document Type: Article

References (22)

1. Crump JA, Luby SP, Mintz ED. The global burden of typhoid fever. Bull WHO. 2004;82:346-352.
2. He XQ. Achievement of control and prevention on typhoid fever in China. Zhong Hua Liu Xing Bing Xue Za Zhi. 2000;21:61-63.
3. Xie GZ, Gu QW, Wang BR, et al. Safety and immune efficacy of Salmonella typhi Vi capsular polysaccharide vaccine. Zhong Guo Sheng Wu Zhi Pin Xue Za Zhi. 1998;11:119-122.
4. Zhou WZ, Zhang LC, Ni DX, Li YY, Zhang HZ. Comparison on the reactogenicity and immunogenicity of China-made and Merieux produced Salmonella typhi Vi polysaccharide vaccines. Zhong Guo Gong Gong Wei Shen. 1999;15:893.
5. Zhou WZ, Ni DX, Li YG, Pan H. Study on immunogenicity of Vi polysaccharide typhoid vaccine. Zhong Guo Gong Gong Wei Sheng. 2000;16:68.
6. Yang HH, Wu CG, Xie GZ, et al. Efficacy trial of Vi polysaccharide vaccine against typhoid fever in South-western China. Bull WHO. 2001;79:625-631.
7. Wang ZG, Zhou WZ, Shi J, Wang TL. Efficacy and side effects following immunization with Salmonella typhi Vi capsular polysaccharide vaccine. Zhong Hua Liu Xing Bing Xue Za Zhi. 1997;18:26-29.
8. Klugman KP, Gilbertson IT, Koornhof HJ, et al. Protective activity of Vi capsular polysaccharide vaccine against typhoid fever. Lancet. 1987;2:1165-1169.
9. Acharya IL, Lowe CU, Thapa R, et al. Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi. A preliminary report. N Engl J Med. 1987;317:1101-1104.
10. Tacket CO, Levine MM, Robbins JB. Persistence of antibody titres three years after vaccination with Vi polysaccharide vaccine against typhoid fever. Vaccine. 1988;6:307-308.
11. Kim YR, Yoo JH, Hur JK, Kang JH, Shin WS, Kang MW. Immunogenicity of Vi capsular polysaccharide vaccine evaluated for three years in Korea. J Korean Med Sci. 1995;10:314-317.
12. Sankilampi U, Honkanen P, Pyhala R, Leinonen M. Associations of prevaccination antibody levels with adverse reactions to pneumococcal and influenza vaccines administered simultaneously in the elderly. Vaccine. 1997;15:1133-1137.
13. Keitel WA, Bond NL, Zahradnik JM, Cramton TA, Robbins JB. Clinical and serological responses following primary and booster immunization with Salmonella typhi Vi capsular polysaccharide vaccines. Vaccine. 1994;12:195-199.
14. Zhang HZ, Ji GX, Zeng M. Detection of typhoid Vi antibody by passive hemagglutination Test. Wei Sheng Wu Xue Mian Yi Xue Jin Zhang. 1996;24:28-31.
15. Tacket CO, Ferreccio C, Robbins JB, et al. Safety and immunogenicity of two Salmonella typhi Vi capsular polysaccharide vaccines. J Infect Dis. 1986;154:342-345.
16. Nolan C, Feeley J, White PJ, Hambie E, Brown S, Wong K. Evaluation of a new assay for Vi antibody in chronic carriers of Salmonella typhi. J Clin Microbiol. 1980;12:22-26.
17. Farrington C, Manning G. Test statistics an sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk. Stat Med. 1990;9:1447-1454.
18. Nichol KL, Donald RM, Hauge M. Side effects associated with pneumococcal vaccination. Am J Infect Control. 1997;25:223-228.
19. Borgono JM, Mclean AA, Vella PP, et al. Vaccination and revaccination with polyvalent pneumococcal polysaccharide vaccines in adults and infants. Proc Soc Exp Biol Med. 1978;157:148-154.
20. Canh Gd, Lin FY, Thiem VD, et al. Effect of dosage on immunogenicity of a Vi conjugate vaccine injected twice into 2- to 5-year-old Vietnamese children. Infect Immun. 2004;72:6586-6588.
21. Lin FY, Ho VA, Khiem HB, et al. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. N Engl J Med. 2001;344:1263-1269.
22. Mai NL, Phan VB, Vo AH, et al. Persistent efficacy of Vi conjugate vaccine against typhoid fever in young children. N Engl J Med. 2003;349:1390-1391.